# US 9,750,705 B2 · Agents useful for treating obesity, diabetes and related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,705 B2
- Document ID: US9750705B2
- Status: Granted
- Kind: B2
- Application number: 14/424,422
- Filed: 2013-08-30
- Published: 2015-08-06
- Granted: 2017-09-05
- Earliest claimed: 2012-08-31
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Gino Cortopassi; Alexey Tomilov
- Web page: https://patentgrep.com/patent/US9750705B2

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/42: Oxazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 2440/14: phosphorylation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases.

## Claims

### Claim 1

A method of treating impaired insulin sensitivity, impaired glucose tolerance or obesity, comprising administering to a subject having the impaired insulin sensitivity, glucose tolerance or obesity an effective regime of idebenone as sole active agent, or a pharmaceutically acceptable salt thereof, thereby treating impaired insulin sensitivity, impaired glucose tolerance or obesity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has type 2 diabetes.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has a body mass index of at least 30.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has or is at risk of metabolic syndrome.

### Claim 5 (depends on 4)

The method of claim 4, wherein the subject has diabetes type 2.

### Claim 6 (depends on 4)

The method of claim 4, wherein the subject is obese.

### Claim 7 (depends on 4)

The method of claim 4, wherein the subject has impaired insulin sensitivity and glucose tolerance.

### Claim 8 (depends on 4)

The method of claim 4, wherein the subject has hyperglycemia.

### Claim 9 (depends on 4)

The method of claim 4, wherein the subject has dyslipidemia.

### Claim 10 (depends on 4)

The method of claim 4, wherein the subject has microalbuminuria.

### Claim 11

A method of treating impaired insulin sensitivity, impaired glucose tolerance or obesity, comprising co-administering to the subject having the impaired insulin sensitivity, glucose tolerance or obesity an effective regime of idebenone and Src I-1, or a pharmaceutically acceptable salt thereof, thereby treating impaired insulin sensitivity, impaired glucose tolerance or obesity.

### Claim 12 (depends on 11)

The method of claim 11, wherein the subject has type 2 diabetes.

### Claim 13 (depends on 11)

The method of claim 11, wherein the subject has a body mass index of at least 30.

### Claim 14 (depends on 11)

The method of claim 11, wherein the subject has or is at risk of metabolic syndrome.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject has diabetes type 2.

### Claim 16 (depends on 14)

The method of claim 14, wherein the subject is obese.

### Claim 17 (depends on 14)

The method of claim 14, wherein the subject has impaired insulin sensitivity and glucose tolerance.

### Claim 18 (depends on 14)

The method of claim 14, wherein the subject has hyperglycemia.

### Claim 19 (depends on 14)

The method of claim 14, wherein the subject has dyslipidemia.

### Claim 20 (depends on 14)

The method of claim 14, wherein the subject has microalbuminuria.